Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1816 | 2475 | 32.6 | 72% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
21 | 4 | UROLOGY & NEPHROLOGY//UROL//JOURNAL OF UROLOGY | 229838 |
272 | 3 | PROSTATE CANCER//PROSTATIC NEOPLASMS//UROL | 43768 |
534 | 2 | ANDROGEN RECEPTOR//PROSTATE CANCER//CASTRATION RESISTANT PROSTATE CANCER | 14838 |
1816 | 1 | ANDROGEN DEPRIVATION THERAPY//BICALUTAMIDE//COMBINED ANDROGEN BLOCKADE | 2475 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ANDROGEN DEPRIVATION THERAPY | authKW | 1366358 | 11% | 41% | 270 |
2 | BICALUTAMIDE | authKW | 521591 | 4% | 41% | 102 |
3 | COMBINED ANDROGEN BLOCKADE | authKW | 424174 | 2% | 72% | 48 |
4 | INTERMITTENT ANDROGEN SUPPRESSION | authKW | 407429 | 1% | 97% | 34 |
5 | ANDROGEN ANTAGONISTS | authKW | 350325 | 2% | 47% | 61 |
6 | DEGARELIX | authKW | 347530 | 1% | 78% | 36 |
7 | PROSTATE CANCER | authKW | 283294 | 32% | 3% | 783 |
8 | ANDROGEN DEPRIVATION | authKW | 255841 | 3% | 25% | 83 |
9 | LHRH AGONIST | authKW | 235004 | 2% | 39% | 49 |
10 | ANTIANDROGEN | authKW | 229538 | 4% | 17% | 109 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Urology & Nephrology | 81975 | 53% | 1% | 1307 |
2 | Oncology | 5823 | 26% | 0% | 650 |
3 | Andrology | 1452 | 2% | 0% | 39 |
4 | Endocrinology & Metabolism | 1303 | 10% | 0% | 246 |
5 | Pharmacology & Pharmacy | 159 | 7% | 0% | 183 |
6 | Medicine, General & Internal | 121 | 5% | 0% | 124 |
7 | Health Care Sciences & Services | 23 | 1% | 0% | 27 |
8 | Geriatrics & Gerontology | 20 | 1% | 0% | 19 |
9 | Nursing | 6 | 1% | 0% | 15 |
10 | Toxicology | 3 | 1% | 0% | 29 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | UROL | 65863 | 31% | 1% | 767 |
2 | STRATEG INVEST COMPREHENS CANC NETWORK | 31212 | 0% | 28% | 9 |
3 | WARD 14 | 27754 | 0% | 75% | 3 |
4 | INTEGRAT CANC THER Y UROL | 25105 | 1% | 11% | 18 |
5 | UROEVIDENCE | 22202 | 0% | 60% | 3 |
6 | J ANESE UROL ASSOC | 16446 | 0% | 67% | 2 |
7 | GERIATR PROGRAM | 13307 | 0% | 10% | 11 |
8 | ABT GASTROENTEROL ENDOKRINOL ZENTRUM INNERE MED | 12336 | 0% | 100% | 1 |
9 | AKKREDITIERTES ZWEITMEINUNGSZENTRUM KEIMZELLTUMOR | 12336 | 0% | 100% | 1 |
10 | AMER FDN UROL DIS PROSTATE QUAL ENHANCEMENT | 12336 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PROSTATE CANCER AND PROSTATIC DISEASES | 51290 | 3% | 6% | 67 |
2 | EUROPEAN UROLOGY SUPPLEMENTS | 46415 | 2% | 8% | 47 |
3 | EUROPEAN UROLOGY | 40003 | 6% | 2% | 153 |
4 | UROLOGY | 25542 | 7% | 1% | 184 |
5 | BJU INTERNATIONAL | 22481 | 5% | 2% | 122 |
6 | PROSTATE | 16005 | 3% | 2% | 77 |
7 | JOURNAL OF UROLOGY | 14698 | 7% | 1% | 183 |
8 | MOLECULAR UROLOGY | 7030 | 0% | 6% | 10 |
9 | PROGRES EN UROLOGIE | 6574 | 2% | 1% | 42 |
10 | BRITISH JOURNAL OF UROLOGY | 5261 | 2% | 1% | 51 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ANDROGEN DEPRIVATION THERAPY | 1366358 | 11% | 41% | 270 | Search ANDROGEN+DEPRIVATION+THERAPY | Search ANDROGEN+DEPRIVATION+THERAPY |
2 | BICALUTAMIDE | 521591 | 4% | 41% | 102 | Search BICALUTAMIDE | Search BICALUTAMIDE |
3 | COMBINED ANDROGEN BLOCKADE | 424174 | 2% | 72% | 48 | Search COMBINED+ANDROGEN+BLOCKADE | Search COMBINED+ANDROGEN+BLOCKADE |
4 | INTERMITTENT ANDROGEN SUPPRESSION | 407429 | 1% | 97% | 34 | Search INTERMITTENT+ANDROGEN+SUPPRESSION | Search INTERMITTENT+ANDROGEN+SUPPRESSION |
5 | ANDROGEN ANTAGONISTS | 350325 | 2% | 47% | 61 | Search ANDROGEN+ANTAGONISTS | Search ANDROGEN+ANTAGONISTS |
6 | DEGARELIX | 347530 | 1% | 78% | 36 | Search DEGARELIX | Search DEGARELIX |
7 | PROSTATE CANCER | 283294 | 32% | 3% | 783 | Search PROSTATE+CANCER | Search PROSTATE+CANCER |
8 | ANDROGEN DEPRIVATION | 255841 | 3% | 25% | 83 | Search ANDROGEN+DEPRIVATION | Search ANDROGEN+DEPRIVATION |
9 | LHRH AGONIST | 235004 | 2% | 39% | 49 | Search LHRH+AGONIST | Search LHRH+AGONIST |
10 | ANTIANDROGEN | 229538 | 4% | 17% | 109 | Search ANTIANDROGEN | Search ANTIANDROGEN |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | NGUYEN, PL , ALIBHAI, SMH , BASARIA, S , D'AMICO, AV , KANTOFF, PW , KEATING, NL , PENSON, DF , ROSARIO, DJ , TOMBAL, B , SMITH, MR , (2015) ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY AND STRATEGIES TO MITIGATE THEM.EUROPEAN UROLOGY. VOL. 67. ISSUE 5. P. 825 -836 | 65 | 63% | 35 |
2 | TROST, LW , SEREFOGLU, E , GOKCE, A , LINDER, BJ , SARTOR, AO , HELLSTROM, WJG , (2013) ANDROGEN DEPRIVATION THERAPY IMPACT ON QUALITY OF LIFE AND CARDIOVASCULAR HEALTH, MONITORING THERAPEUTIC REPLACEMENT.JOURNAL OF SEXUAL MEDICINE. VOL. 10. ISSUE . P. 84 -101 | 104 | 60% | 8 |
3 | KUNATH, F , GROBE, HR , RUCKER, G , MOTSCHALL, E , ANTES, G , DAHM, P , WULLICH, B , MEERPOHL, JJ , (2014) NON-STEROIDAL ANTIANDROGEN MONOTHERAPY COMPARED WITH LUTEINISING HORMONE-RELEASING HORMONE AGONISTS OR SURGICAL CASTRATION MONOTHERAPY FOR ADVANCED PROSTATE CANCER.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 6. P. - | 86 | 64% | 2 |
4 | SHORE, ND , ABRAHAMSSON, PA , ANDERSON, J , CRAWFORD, ED , LANGE, P , (2013) NEW CONSIDERATIONS FOR ADT IN ADVANCED PROSTATE CANCER AND THE EMERGING ROLE OF GNRH ANTAGONISTS.PROSTATE CANCER AND PROSTATIC DISEASES. VOL. 16. ISSUE 1. P. 7-15 | 63 | 78% | 15 |
5 | SCHULMAN, CC , IRANI, J , MOROTE, J , SCHALKEN, JA , MONTORSI, F , CHLOSTA, PL , HEIDENREICH, A , (2010) ANDROGEN-DEPRIVATION THERAPY IN PROSTATE CANCER: A EUROPEAN EXPERT PANEL REVIEW.EUROPEAN UROLOGY SUPPLEMENTS. VOL. 9. ISSUE 7. P. 675 -691 | 75 | 74% | 9 |
6 | SHIOTA, M , ETO, M , (2016) CURRENT STATUS OF PRIMARY PHARMACOTHERAPY AND FUTURE PERSPECTIVES TOWARD UPFRONT THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.INTERNATIONAL JOURNAL OF UROLOGY. VOL. 23. ISSUE 5. P. 360 -369 | 59 | 59% | 4 |
7 | LIAW, BC , SHEVACH, J , OH, WK , (2015) SYSTEMIC THERAPY FOR THE TREATMENT OF HORMONE-SENSITIVE METASTATIC PROSTATE CANCER: FROM INTERMITTENT ANDROGEN DEPRIVATION THERAPY TO CHEMOTHERAPY.CURRENT UROLOGY REPORTS. VOL. 16. ISSUE 3. P. - | 50 | 88% | 2 |
8 | ABRAHAMSSON, PA , (2010) POTENTIAL BENEFITS OF INTERMITTENT ANDROGEN SUPPRESSION THERAPY IN THE TREATMENT OF PROSTATE CANCER: A SYSTEMATIC REVIEW OF THE LITERATURE.EUROPEAN UROLOGY. VOL. 57. ISSUE 1. P. 49-59 | 41 | 95% | 100 |
9 | ALLAN, CA , COLLINS, VR , FRYDENBERG, M , MCLACHLAN, RI , MATTHIESSON, KL , (2014) ANDROGEN DEPRIVATION THERAPY COMPLICATIONS.ENDOCRINE-RELATED CANCER. VOL. 21. ISSUE 4. P. T119 -T129 | 59 | 70% | 10 |
10 | SINGER, EA , GOLIJANIN, DJ , MIYAMOTO, H , MESSING, EM , (2008) ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 9. ISSUE 2. P. 211-228 | 80 | 60% | 20 |
Classes with closest relation at Level 1 |